WO2011044563A3 - Il-17 family cytokine compositions and uses - Google Patents

Il-17 family cytokine compositions and uses Download PDF

Info

Publication number
WO2011044563A3
WO2011044563A3 PCT/US2010/052194 US2010052194W WO2011044563A3 WO 2011044563 A3 WO2011044563 A3 WO 2011044563A3 US 2010052194 W US2010052194 W US 2010052194W WO 2011044563 A3 WO2011044563 A3 WO 2011044563A3
Authority
WO
WIPO (PCT)
Prior art keywords
family cytokine
cytokine compositions
proteins
molecules
methods
Prior art date
Application number
PCT/US2010/052194
Other languages
French (fr)
Other versions
WO2011044563A2 (en
Inventor
Christopher K. Garcia
Sashank Reddy
Gregory James Sieczkiewicz
Thomas M. Barnes
Michael M. Schmidt
Bracken M. King
Lauren K. Ely
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Eleven Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University, Eleven Biotherapeutics, Inc. filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Priority to EA201270528A priority Critical patent/EA201270528A1/en
Priority to EP10822826.3A priority patent/EP2485763A4/en
Priority to CA2777222A priority patent/CA2777222A1/en
Priority to BR112012008444A priority patent/BR112012008444A2/en
Priority to CN2010800536540A priority patent/CN102648002A/en
Priority to US13/501,244 priority patent/US20130064788A1/en
Priority to AU2010303166A priority patent/AU2010303166A1/en
Priority to JP2012533384A priority patent/JP2013507132A/en
Publication of WO2011044563A2 publication Critical patent/WO2011044563A2/en
Publication of WO2011044563A3 publication Critical patent/WO2011044563A3/en
Priority to IL219209A priority patent/IL219209A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL- 17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.
PCT/US2010/052194 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses WO2011044563A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EA201270528A EA201270528A1 (en) 2009-10-10 2010-10-11 COMPOSITIONS OF CYTOKINES IL-17 FAMILIES AND THEIR APPLICATION
EP10822826.3A EP2485763A4 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses
CA2777222A CA2777222A1 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses
BR112012008444A BR112012008444A2 (en) 2009-10-10 2010-10-11 isolated protein, pharmaceutical composition, methods for modulating an immune or inflammatory response in a subject, for treating an ir-17 mediated disorder in a subject and for preparing a recombinant protein, isolated nucleic acid, and recombinant host cell
CN2010800536540A CN102648002A (en) 2009-10-10 2010-10-11 IL-17 family cytokine compositions and uses
US13/501,244 US20130064788A1 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses
AU2010303166A AU2010303166A1 (en) 2009-10-10 2010-10-11 IL-17 family cytokine compositions and uses
JP2012533384A JP2013507132A (en) 2009-10-10 2010-10-11 IL-17 family cytokine composition and use
IL219209A IL219209A0 (en) 2009-10-10 2012-04-15 Il-17 family cytokine compositions and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27877909P 2009-10-10 2009-10-10
US61/278,779 2009-10-10

Publications (2)

Publication Number Publication Date
WO2011044563A2 WO2011044563A2 (en) 2011-04-14
WO2011044563A3 true WO2011044563A3 (en) 2011-06-03

Family

ID=43857433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/052194 WO2011044563A2 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses

Country Status (11)

Country Link
US (1) US20130064788A1 (en)
EP (1) EP2485763A4 (en)
JP (1) JP2013507132A (en)
KR (1) KR20120093932A (en)
CN (1) CN102648002A (en)
AU (1) AU2010303166A1 (en)
BR (1) BR112012008444A2 (en)
CA (1) CA2777222A1 (en)
EA (1) EA201270528A1 (en)
IL (1) IL219209A0 (en)
WO (1) WO2011044563A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
JP5969458B2 (en) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ Albumin derivatives and variants
CN107337735B (en) 2010-07-29 2021-06-22 巴扎德制药公司 Chimeric IL-1 receptor type I agonists and antagonists
US20140105855A1 (en) * 2011-04-06 2014-04-17 Kenan Christopher Garcia Structural based design of il-17 dominant negative mutants
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
LT2768859T (en) * 2011-10-19 2018-06-11 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
US20140314798A1 (en) * 2011-10-21 2014-10-23 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
MX2014010278A (en) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Albumin variants.
JP2013253842A (en) * 2012-06-06 2013-12-19 Univ Of Tokyo Screening method for peptide connected to target molecule depending on ph
US9834601B2 (en) 2012-06-12 2017-12-05 Orega Biotech Antagonists of IL-17 isoforms and their uses
EP3417878A1 (en) * 2012-06-12 2018-12-26 Orega Biotech Antagonists of il-17 isoforms and their uses
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
BR112015022587A2 (en) 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc chimeric cytokine formulations for ocular delivery
SG10201912901YA (en) * 2013-04-17 2020-02-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
AU2016308504A1 (en) 2015-08-20 2018-01-18 Albumedix Ltd. Albumin variants and conjugates
CN108883166B (en) * 2016-03-25 2023-06-02 国立大学法人大阪大学 Conjugate vaccine targeting in vivo proteins which are the main cause of disease
EP3445352A4 (en) * 2016-04-19 2019-12-11 Azura Opthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
CN111093678A (en) * 2017-07-21 2020-05-01 克利夫兰诊所基金会 SBE aptamers for the treatment of IL-17 a-associated diseases and conditions
BR112020023167A2 (en) 2018-05-14 2021-02-09 Werewolf Therapeutics, Inc. activatable cytokine polypeptides and methods of using these
EP3794024B1 (en) 2018-05-14 2023-05-10 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
JP2022527345A (en) 2019-04-03 2022-06-01 オレガ・バイオテック Combined therapy based on PD1 and IL-17B inhibitors
CN114450022A (en) 2019-05-14 2022-05-06 狼人治疗公司 Separation fraction and method of use thereof
US20220281967A1 (en) * 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
KR102265435B1 (en) * 2019-08-20 2021-06-15 주식회사 케어젠 Peptide having activities of skin whitening and uses thereof
CA3166357A1 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
EP4110810A1 (en) 2020-02-28 2023-01-04 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
WO2022032592A1 (en) * 2020-08-13 2022-02-17 Tsinghua University Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
CN113403259B (en) * 2021-06-04 2023-01-17 华南农业大学 Additive for improving development quality of cloned embryos and application thereof
CN113563453A (en) * 2021-07-23 2021-10-29 四川大学 Preparation and application of chicken interleukin 17B recombinant lactobacillus immune preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218065A1 (en) * 2006-03-10 2007-09-20 Jaspers Stephen R Antibodies that bind both il-17a and il-17f and methods of using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4373495B2 (en) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション IL-17 receptor
US6569419B2 (en) * 2000-02-29 2003-05-27 Zymogenetics, Inc. Methods for promoting production of myelin by Schwann cells
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20060083713A1 (en) * 2000-10-13 2006-04-20 Eli Lilly And Company Methods of using a human il-17 related polypeptide to treat disease
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US20040115191A1 (en) * 2002-01-24 2004-06-17 Moore Emma E Method for treating psoriasis
WO2002076386A2 (en) * 2001-03-26 2002-10-03 Zymogenetics, Inc. Method of inducing proliferation of retinal stem cells
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2751414T5 (en) * 2003-07-08 2024-04-23 Novartis Pharma Ag Antagonist antibodies to heterologous IL-17 A/F polypeptides
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1996616A1 (en) * 2006-02-10 2008-12-03 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
MX2009001620A (en) * 2006-08-11 2009-02-23 Schering Corp Antibodies to il-17a.
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
EP2144928A2 (en) * 2007-04-20 2010-01-20 Amgen Inc. Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
EP2142568B1 (en) * 2007-04-27 2014-03-19 ZymoGenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218065A1 (en) * 2006-03-10 2007-09-20 Jaspers Stephen R Antibodies that bind both il-17a and il-17f and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYMOWITZ ET AL.: "IL-17s adopt a cystine knot fold structure and activity of a novel cytokine, IL- 17F, and implications for receptor binding", EMBO JOURNAL, vol. 20, no. 19, 2001, pages 5332 - 5341, XP008155759 *

Also Published As

Publication number Publication date
CN102648002A (en) 2012-08-22
US20130064788A1 (en) 2013-03-14
EA201270528A1 (en) 2012-12-28
JP2013507132A (en) 2013-03-04
KR20120093932A (en) 2012-08-23
EP2485763A2 (en) 2012-08-15
WO2011044563A2 (en) 2011-04-14
BR112012008444A2 (en) 2019-09-24
CA2777222A1 (en) 2011-04-14
IL219209A0 (en) 2012-06-28
EP2485763A4 (en) 2013-10-30
AU2010303166A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
WO2011044563A3 (en) Il-17 family cytokine compositions and uses
EP2679234A3 (en) Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
WO2011011797A3 (en) Cytokine compositions and methods of use thereof
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2013151736A3 (en) In vivo production of proteins
MY162511A (en) Engineered anti-tslp antibody
MX2012011771A (en) Aptamers to î²-ngf and their use in treating î²-ngf mediated diseases and disorders.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
AU2009260320A8 (en) Antibodies to IL-6 and their uses
WO2012058393A3 (en) Dkk1 antibodies and methods of use
MX2009006471A (en) Engineered anti-tslp antibody.
MX2010008688A (en) Engineered anti-tslpr antibodies.
WO2008106134A3 (en) Engineered anti-il-23r antibodies
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2013173761A3 (en) St2 antigen binding proteins
MX2009009079A (en) Engineered anti-il-23p19 antibodies.
MX2009009080A (en) Engineered anti-il-23p19 antibodies.
MX2011011768A (en) Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both.
MA32980B1 (en) Proteins binding to myostatin
MX2012000396A (en) Methods and compositions for use in cellular therapies.
ZA201008379B (en) Glucocorticoid mimetics,methods of making them,pharmaceutical compositions,and uses thereof
WO2010132370A8 (en) Soluble trem-1 family peptides and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080053654.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822826

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2777222

Country of ref document: CA

Ref document number: 2012533384

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 219209

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010303166

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1094/KOLNP/2012

Country of ref document: IN

Ref document number: 201270528

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20127011769

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010822826

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010303166

Country of ref document: AU

Date of ref document: 20101011

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13501244

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012008444

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012008444

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120410